Medical Developments International Limited (ASX: MVP) has lately come into spotlight with many developments which include:
 
Distribution deal with McKesson Corp: The group has finalised a distribution deal with McKesson Corp. (largest healthcare supply chain in North America) for the distribution of “Space Chamber” anti-static Respiratory Devices in the United States of America. Further, McKesson has placed its first order for stock which has been said to be delivered by the end of December 2016.
 
Term sheet signed with CSIRO: The group had also signed a Term Sheet with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), to conduct a Research and Development program into new manufacturing technologies for pharmaceutical products.
 
The group had earlier reported that FY16 earnings before interest, tax, depreciation and amortisation were of the order of $3.4 million, which is up 29% over previous corresponding year, while revenues surged 33%. The group’s net profit after tax was $1.6 million. MVP had received $15 million in cash milestone payments and is debt free. MVP had also received regulatory approval and the marketing authorisation for the sale of Penthrox in the United Arab Emirates (UAE) sometime back, and in fact, the FY16 revenue growth was witnessed in support of the 147% growth in international sales of Penthrox in various key markets.
 

Full year FY16 Performance (Source: Company Reports)
 
Despite the developments, the stock has fallen 10.19% in the last one month (as at November 11, 2016). It may be a little early to say about the growth prospects as the stock has been on a roller coaster for quite some time with many ups and downs.

---

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in:  BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.